Long-term results of International Breast Cancer Study Group Trial VIII: adjuvant chemotherapy plus goserelin compared with either therapy alone for premenopausal patients with node-negative breast cancer by Karlsson, P et al.
Annals of Oncology 22: 2216–2226, 2011
doi:10.1093/annonc/mdq735
Published online 16 February 2011
original article
Long-term results of International Breast Cancer Study
Group Trial VIII: adjuvant chemotherapy plus goserelin
compared with either therapy alone for premenopausal
patients with node-negative breast cancer
P. Karlsson1*, Z. Sun2, D. Braun2, K. N. Price3, M. Castiglione-Gertsch4, M. Rabaglio5,
R. D. Gelber6, D. Crivellari7, J. Collins8, E. Murray9, K. Zaman10, M. Colleoni11, B. A. Gusterson12,
G. Viale13, M. M. Regan2, A. S. Coates14,15 & A. Goldhirsch16,17
1Department of Oncology, Institute of Clinical Sciences, Sahlgrenska Academy at University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden;
2IBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Department of Biostatistics, Harvard School of
Public Health; 3IBCSG Statistical Center, Frontier Science and Technology Research Foundation, Boston, USA; 4Unite´ de Onco-Gyne´cologie Me´dicale Departement de
Me´decine Hoˆpitaux Universitaires de Gene`ve, Gene`ve; 5IBCSG Coordinating Center and Department of Medical Oncology, Inselspital, Bern, Switzerland; 6IBCSG
Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute and Frontier Science and Technology Research Foundation,
Harvard School of Public Health, Harvard Medical School, Boston, USA; 7Department of Medical Oncology, Centro di Riferimento Oncologico, Aviano, Italy; 8Department
of Surgery, The Royal Melbourne Hospital, Melbourne, Australia; 9Department of Radiation Oncology, Groote Shuur Hospital, University of Cape Town, Cape Town,
South Africa; 10Department of Medical Oncology, Centre Hospitalier Universitaire Vaudois, Centre du Cancer Lausanne, Lausanne and Swiss Group for Clinical Cancer
Research (SAKK), Bern, Switzerland; 11Department of Medicine, Research Unit in Medical Senology, European Institute of Oncology, Milan, Italy; 12IBCSG Pathology
Review Office, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK; 13IBCSG Pathology Office, Division of Pathology and Laboratory Medicine,
European Institute of Oncology, University of Milan, Milan, Italy; 14International Breast Cancer Study Group, Bern, Switzerland; 15School of Public Health,
University of Sydney, Sydney, Australia; 16Department of Medicine, European Institute of Oncology, Milan, Italy; 17Oncology Institute of Southern Switzerland, Bellinzona,
Switzerland
Received 28 July 2010; revised 19 November 2010; accepted 22 November 2010
Background: The International Breast Cancer Study Group Trial VIII compared long-term efficacy of endocrine
therapy (goserelin), chemotherapy [cyclophosphamide, methotrexate and fluorouracil (CMF)], and chemoendocrine
therapy (CMF followed by goserelin) for pre/perimenopausal women with lymph-node-negative breast cancer.
Patients and methods: From 1990 to 1999, 1063 patients were randomized to receive (i) goserelin for 24 months
(n = 346), (ii) six courses of ‘classical’ CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy (n = 360),
or (iii) six courses of CMF plus 18 months goserelin (CMF/ goserelin; n = 357). Tumors were classified as estrogen
receptor (ER) negative (19%), ER positive (80%), or ER unknown (1%); 19% of patients were younger than 40. Median
follow-up was 12.1 years.
Results: For the ER-positive cohort, sequential therapy provided a statistically significant benefit in disease-free
survival (DFS) (12-year DFS = 77%) compared with CMF alone (69%) and goserelin alone (68%) (P = 0.04 for each
comparison), due largely to the effect in younger patients. Patients with ER-negative tumors whose treatment included
CMF had similar DFS (12-year DFS CMF = 67%; 12-year DFS CMF/ goserelin = 69%) compared with goserelin alone
(12-year DFS = 61%, P = NS).
Conclusions: For pre/perimenopausal women with lymph-node-negative ER-positive breast cancer, CMF followed
by goserelin improved DFS in comparison with either modality alone. The improvement was the most pronounced in
those aged below 40, suggesting an endocrine effect of prolonged CMF-induced amenorrhea.
Key words: amenorrhea, breast cancer, chemotherapy, goserelin, hormonal therapy, node negative
introduction
A recent survey among researchers in the breast cancer field [1]
found that the identification of hormone receptor-positive
breast cancer patients who might derive equal benefit from
endocrine treatment alone without the addition of adjuvant
chemotherapy is one of the most important current clinical
research topics. High levels of estrogen receptor expression
predict efficacy of endocrine treatment [2], while patients with
tumors having lower quantitative estrogen receptor expression
seem to benefit most from the addition of chemotherapy to
endocrine treatment alone [3, 4]. Some studies have found
higher levels of Ki-67-labeling index to be predictive for
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chemotherapy benefit in the neoadjuvant setting, while others
have not [5]. Studies in the adjuvant setting indicate
a prognostic effect of Ki-67 but no clear predictive value for
chemotherapy efficacy [6]. Various new multigene assays are
being developed. Studies comparing different assays indicate
similarities between them insofar as the genes selected mainly
represent three domains: the steroid hormone expression
pathways, the epidermal growth factor system, and
proliferation markers [7]. The two former are useful for
treatment prediction, while proliferation markers seem to be
more prognostic. Although multigene assays are promising,
high-quality immunohistochemistry and breast pathology
remain the cornerstones for adjuvant treatment selection in
most places. The International Breast Cancer Study Group
(IBCSG) previously published results of Trial VIII at a median
follow-up of 7 years, comparing chemotherapy plus ovarian
function suppression in sequence to each modality alone in
premenopausal patients with node-negative breast cancer [8].
Since a substantial proportion of the breast cancer events in the
hormone receptor-positive group occur many years after
diagnosis, it is important to explore the treatment efficacy
pattern with long-term follow-up. The aim of the present study
was to update the results of IBCSG Trial VIII with 12.1 years
median follow-up comparing treatment efficacy pattern
according to centrally determined ER expression and age at
start of treatment.
patients and methods
Details about IBCSG Trial VIII have been previously published [8]. In
short, Trial VIII is a randomized trial designed to evaluate the role of the
adjuvant therapy with the sequential combination of chemotherapy and
ovarian function suppression, compared with each modality alone, for pre-
and perimenopausal patients with lymph-node-negative breast cancer.
From March 1990 to October 1999, 1063 pre- and perimenopausal women
were randomly assigned to receive either (i) 24 monthly subcutaneous
implants of goserelin every 28 days, (ii) six 28-day courses of ‘classical’
CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy, or
(iii) six 28-day courses of classical CMF followed by 18 monthly implants of
goserelin. Initially the trial included a no adjuvant treatment group, which
was discontinued in 1992, on the basis of results from other trials, after 46
patients had been randomized. Systemic adjuvant therapy was to begin
within 6 weeks of primary surgery. For the sequential treatment arm, the
first goserelin implant was scheduled to be given on day 28 of the sixth
courses of CMF. Pre- or perimenopausal status was defined as having one
of the following sets of characteristics: (i) aged older than 52 years with last
normal menstrual period within 1 year, (ii) aged 52 years or younger with
last normal menstrual period within 3 years, (iii) aged 55 years or younger
with hysterectomy but no bilateral oophorectomy (for patients aged older
than 45 years, biochemical confirmation for ovarian function was
requested), or (iv) biochemical evidence of continuing ovarian function
(for doubtful cases). The randomization was stratified according to locally
determined estrogen receptor (ER) status (negative, positive, or unknown),
whether radiotherapy was planned after breast-conserving surgical
procedure (yes or no), and by participating institution.
In 1998, a protocol amendment restricted enrollment to patients with
ER-positive tumors, based on evidence from other trials that ovarian
ablation might not be effective for patients with ER-negative tumors. The
intention to perform separate analyses according to ER status was specified
in the original protocol. A retrospective collection of tumor blocks led to
the central evaluation of ER expression by immunohistochemical (IHC)
assay for 867 patients. Centrally determined ER status was considered
negative if <1% of the cells were stained. For the remaining 196 patients
without centrally reviewed tumors, the locally evaluated ER status was used
[ER status was determined hierarchically from quantitative IHC (none
versus 1%–100%); biochemical assay (0 versus >0 fmol/mg cytosol
protein); or qualitative IHC (negative versus borderline/positive/strongly
positive) results]. The locally obtained ER results were in concordance with
the central IHC review for 81.2% of the patients [9].
statistical considerations
The end points of interest were disease-free survival (DFS), overall survival
(OS), and breast cancer-free interval (BCFI). DFS was defined as the length
of time from the date of randomization to any invasive breast cancer relapse
(including ipsilateral or contralateral breast recurrence), the appearance of
a second (nonbreast) malignancy, or death, whichever occurred first or was
censored at date of last follow-up. OS was defined as the length of time
from the date of randomization to death from any cause. BCFI was defined
as the length of time from the date of randomization to any invasive breast
cancer relapse (including ipsilateral or contralateral breast recurrence),
according to the standardized definitions of efficacy end points (STEEP)
criteria [10] and was censored at date of last follow-up or at date of death
without relapse.
DFS, OS, and BCFI percentages, standard errors, and treatment effect
comparisons were estimated using the Kaplan–Meier method, Greenwood’s
formula, and log-rank tests, respectively. Cox proportional hazards
regression models were used to control for prognostic features and to
estimate hazard ratios (HR) and 95% confidence intervals (CI) for the
treatment comparisons.
Treatment–covariate interactions were studied using nonparametric
Subpopulation Treatment Effect Pattern Plot (STEPP) methodology [11].
STEPP involves defining several overlapping subgroups of patients on the
basis of a covariate of interest and studying the resulting pattern of the
treatment effects estimated within each subgroup. In this report, age was
the covariate of interest, and treatment effects estimated within each age
subpopulation were measured in terms of 5-year and 12-year DFS
percentages. Probability values for the interaction test of treatment and age
were provided on the basis of simulations.
results
The median follow-up for this analysis was 12.1 years (range
0.6–18.4). Patients’ tumors were classified as ER positive among
80% (n = 851) of patients, ER negative among 19% (n = 205),
and unknown among 1% (n = 7) patients. The baseline
patients’ characteristics according to ER status are shown in
Table 1. The treatment groups were well balanced.
Table 2 summarizes the results for cohorts defined according
to ER status and age for the three end points: DFS, OS, and
BCFI. There were no statistically significant differences in
overall survival between any of the treatment groups (Figures
1B and E and 2B and E).
For patients with ER-positive disease, the 12-year DFS was
68% in the goserelin alone group, 69% in the CMF alone
group, and 77% in the CMF followed by goserelin (CMF/
goserelin) group; the 12-year BCFI was 71% in the goserelin
alone group, 71% in the CMF alone group, and 81% in the
CMF/ goserelin group. There were no statistically significant
differences between CMF alone versus goserelin alone in DFS
and BCFI [HR 0.99 (95% CI 0.74–1.34) for DFS, and HR 0.96
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(95% CI 0.70–1.32) for BCFI]. CMF/ goserelin significantly
improved DFS and BCFI compared with goserelin alone [HR
0.71 (95% CI 0.51–0.98, P = 0.04) for DFS, and HR 0.63 (95%
CI 0.45–0.90, P = 0.01) for BCFI]. CMF/ goserelin also
significantly improved DFS and BCFI compared with CMF
alone [HR 0.71 (95% CI 0.52–0.99, P = 0.04) for DFS, and HR
0.66 (95% CI 0.46–0.94, P = 0.02) for BCFI] (Table 2, Figure 1A
and C). The superiority in treatment efficacy of CMF/
goserelin compared with goserelin alone or with CMF alone
was most pronounced for patients with ER-positive tumors
who were younger than 40 years of age [compared with
goserelin alone, HR 0.41 (95% CI 0.20–0.83, P = 0.01) for DFS,
and HR 0.40 (95% CI 0.19–0.83, P = 0.01) for BCFI; compared
with CMF alone, HR 0.42 (95% CI 0.21–0.85, P = 0.02) for
DFS, and HR 0.39 (95% CI 0.19–0.81, P = 0.01) for BCFI]
(Table 2, Figure 2A and C). The interactions between the
Table 1. Patient and tumor characteristics for pre- and perimenopausal patients with lymph-node-negative breast cancer and cohorts defined according
to estrogen receptor (ER) status
Goserelin · 24, n (%) CMF · 6, n (%) CMF · 6/goserelin · 18, n (%) Total, n (%)
ER-positive cohort n = 278 n = 291 n = 282 n = 851
Age (years)
£34 11 (4) 16 (6) 16 (6) 43 (5)
35–39 36 (13) 36 (12) 37 (13) 109 (13)
40–44 65 (23) 88 (30) 69 (24) 222 (26)
45–49 115 (41) 105 (36) 105 (37) 325 (38)
‡50 51 (18) 46 (16) 55 (20) 152 (18)
Primary surgical treatment
Total mastectomy 119 (43) 126 (43) 121 (43) 366 (43)
Breast conservation
With RT planned 148 (53) 151 (52) 146 (52) 445 (52)
With no RT planned 11 (4) 14 (5) 15 (5) 40 (5)
Tumor size (cm)
£1.0 27 (10) 37 (13) 44 (16) 108 (13)
1.1–2.0 149 (54) 151 (52) 146 (52) 446 (52)
>2 100 (36) 98 (34) 90 (32) 288 (34)
Unknown 2 (1) 5 (2) 2 (1) 9 (1)
Tumor grade
1 52 (19) 46 (16) 77 (27) 175 (21)
2 148 (53) 146 (50) 129 (46) 423 (50)
3 76 (27) 93 (32) 74 (26) 243 (29)
Unknown 2 (1) 6 (2) 2 (1) 10 (1)
ER-negative cohort n = 65 n = 68 n = 72 n = 205
Age (years)
£34 5 (8) 6 (9) 4 (6) 15 (7)
35–39 15 (23) 10 (15) 16 (22) 41 (20)
40–44 15 (23) 18 (26) 22 (31) 55 (27)
45–49 24 (37) 24 (35) 20 (28) 68 (33)
‡50 6 (9) 10 (15) 10 (14) 26 (13)
Primary surgical treatment
Total mastectomy 34 (52) 31 (46) 35 (49) 100 (49)
Breast conservation
With RT planned 27 (42) 30 (44) 33 (46) 90 (44)
With no RT planned 4 (6) 7 (10) 4 (6) 15 (7)
Tumor size (cm)
£1.0 5 (8) 5 (7) 5 (7) 15 (7)
1.1–2.0 31 (48) 21 (31) 28 (39) 80 (39)
>2 29 (45) 42 (62) 37 (51) 108 (53)
Unknown 0 (0) 0 (0) 2 (3) 2 (1)
Tumor grade
1 1 (2) 2 (3) 3 (4) 6 (3)
2 12 (18) 16 (24) 16 (22) 44 (21)
3 52 (80) 49 (72) 51 (71) 152 (74)
Unknown 0 (0) 1 (1) 2 (3) 3 (1)
CMF, cyclophosphamide, methotrexate and fluorouracil; RT, radiation therapy.
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Table 2. Disease-free survival (DFS), overall survival (OS), and breast cancer-free interval (BCFI) for 1063 pre- and perimenopausal women with lymph-node-
negative breast cancer according to randomized treatment group at a median follow-up for 12.1 years in cohorts defined by ER status and age at study entry
Total
patients
Total
events
5-year
DFS % 6 SE
12-year
DFS % 6 SE
Comparison HR Lower
95% CI
Upper
95% CI
Log-rank
P-value
DFS
ER+ Gos 278 84 82 6 2 68 6 3 C versus G 0.99 0.74 1.34 0.96
CMF 291 88 84 6 2 69 6 3 C/G versus G 0.71 0.51 0.98 0.04
CMF/Gos 282 63 88 6 2 77 6 3 C/G versus C 0.71 0.52 0.99 0.04
ER+ age <40 Gos 47 22 72 6 7 51 6 8 C versus G 1.01 0.56 1.82 0.98
CMF 52 22 67 6 7 55 6 7 C/G versus G 0.41 0.20 0.83 0.01
CMF/Gos 53 12 89 6 4 77 6 6 C/G versus C 0.42 0.21 0.85 0.02
ER+ age ‡40 Gos 231 62 84 6 2 72 6 3 C versus G 1.00 0.71 1.42 0.99
CMF 239 66 88 6 2 72 6 3 C/G versus G 0.82 0.56 1.18 0.28
CMF/Gos 229 51 88 6 2 77 6 3 C/G versus C 0.82 0.57 1.18 0.29
ER2 Gos 65 26 71 6 6 61 6 6 C versus G 0.86 0.49 1.49 0.58
CMF 68 25 76 6 5 67 6 6 C/G versus G 0.71 0.40 1.24 0.23
CMF/Gos 72 23 85 6 4 69 6 6 C/G versus C 0.81 0.46 1.43 0.47
ER2 age <40 Gos 20 7 75 6 10 64 6 11 C versus G 0.93 0.31 2.79 0.90
CMF 16 6 81 6 10 74 6 11 C/G versus G 1.03 0.36 2.94 0.96
CMF/Gos 20 7 80 6 9 65 6 11 C/G versus C 1.02 0.34 3.04 0.98
ER2 age ‡40 Gos 45 19 69 6 7 60 6 7 C versus G 0.81 0.43 1.53 0.52
CMF 52 19 75 6 6 65 6 7 C/G versus G 0.60 0.31 1.18 0.14
CMF/Gos 52 16 87 6 5 70 6 7 C/G versus C 0.74 0.38 1.44 0.38
Total
patients
Total
events
5-year
OS % 6 SE
12-year
OS % 6 SE
HR Lower
95% CI
Upper
95% CI
P-value
OS
ER+ Gos 278 34 97 6 1 87 6 2 C versus G 1.25 0.80 1.96 0.33
CMF 291 43 94 6 1 84 6 2 C/G versus G 0.86 0.53 1.42 0.56
CMF/Gos 282 29 97 6 1 90 6 2 C/G versus C 0.68 0.42 1.09 0.11
ER+ age <40 Gos 47 10 96 6 3 76 6 8 C versus G 1.11 0.47 2.62 0.81
CMF 52 11 92 6 4 78 6 6 C/G versus G 0.41 0.14 1.21 0.11
CMF/Gos 53 5 98 6 2 92 6 4 C/G versus C 0.40 0.14 1.14 0.09
ER+ age ‡40 Gos 231 24 97 6 1 89 6 2 C versus G 1.32 0.78 2.23 0.31
CMF 239 32 95 6 1 85 6 3 C/G versus G 1.04 0.59 1.83 0.89
CMF/Gos 229 24 97 6 1 90 6 2 C/G versus C 0.78 0.46 1.32 0.36
ER2 Gos 65 17 86 6 4 73 6 6 C versus G 0.88 0.45 1.75 0.73
CMF 68 16 85 6 4 78 6 5 C/G versus G 0.81 0.41 1.60 0.54
CMF/Gos 72 16 89 6 4 80 6 5 C/G versus C 0.90 0.45 1.80 0.77
ER2 age <40 Gos 20 5 85 6 8 75 6 10 C versus G 0.51 0.10 2.65 0.43
CMF 16 2 88 6 8 88 6 8 C/G versus G 0.83 0.22 3.08 0.78
CMF/Gos 20 4 85 6 8 80 6 9 C/G versus C 1.53 0.28 8.35 0.62
ER2 age ‡40 Gos 45 12 87 6 5 72 6 7 C versus G 1.00 0.46 2.15 0.99
CMF 52 14 85 6 5 75 6 6 C/G versus G 0.80 0.36 1.79 0.59
CMF/Gos 52 12 90 6 4 80 6 6 C/G versus C 0.78 0.36 1.70 0.54
Total
patients
Total
events
5-year
BCFI % 6 SE
12-year
BCFI % 6 SE
HR Lower
95% CI
Upper
95% CI
P-value
BCFI
ER+ Gos 278 77 83 6 2 71 6 3 C versus G 0.96 0.70 1.32 0.80
CMF 291 78 86 6 2 71 6 3 C/G versus G 0.63 0.45 0.90 0.01
CMF/Gos 282 52 90 6 2 81 6 3 C/G versus C 0.66 0.46 0.94 0.02
ER+ age <40 Gos 47 21 72 6 7 54 6 8 C versus G 1.05 0.58 1.92 0.86
CMF 52 22 67 6 7 55 6 7 C/G versus G 0.40 0.19 0.83 0.01
CMF/Gos 53 11 89 6 4 77 6 6 C/G versus C 0.39 0.19 0.81 0.01
ER+ age ‡40 Gos 231 56 86 6 2 74 6 3 C versus G 0.94 0.65 1.36 0.75
CMF 239 56 91 6 2 75 6 3 C/G versus G 0.72 0.48 1.08 0.11
CMF/Gos 229 41 90 6 2 82 6 3 C/G versus C 0.77 0.52 1.16 0.21
ER2 Gos 65 24 72 6 6 64 6 6 C versus G 0.82 0.46 1.46 0.50
CMF 68 22 81 6 5 71 6 6 C/G versus G 0.68 0.38 1.24 0.21
CMF/Gos 72 20 85 6 4 72 6 5 C/G versus C 0.81 0.44 1.49 0.51
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treatments and age groups (age <40 versus age ‡40) were
assessed using Cox proportional hazard models and the
interaction P values were 0.16 and 0.21 for DFS and BCFI,
respectively.
In the small ER-negative cohort, there were no significant
differences between the treatment groups. However, patients
with ER-negative tumors who received treatments that
included CMF appeared to have better DFS and BCFI (12-year
DFS for CMF = 67% and 12-year DFS for CMF/ goserelin =
69%; 12-year BCFI for CMF = 71% and 12-year BCFI for
CMF/ goserelin = 72%) than if they received goserelin alone
(12-year DFS = 61%; 12-year BCFI = 64%) (Table 2, Figure 1D
and F).
Multivariate Cox regression analyses on DFS in the ER-
positive cohort indicated that age <40, breast-conserving
surgery without radiotherapy and grade 2 or 3 tumors were
significant risk factors. None of the risk factors were significant
in the ER-negative cohort (Table 3).
STEPP analyses were used to explore the pattern of treatment
effect differences in terms of 5- and 12-year DFS percentages
according to the age at diagnosis in the ER-positive cohort. For
this sliding window STEPP analysis, each subpopulation
contained 165 patients, and each subsequent subpopulation
was formed moving from left to right by dropping 30 patients
with the lowest age and adding 30 patients with the next
higher age. The x coordinate indicates the median age for the
patients in each subpopulation. The y coordinate indicates the
5- or 12-year DFS percentages estimated using the Kaplan–
Meier method on data from patients in each subpopulation.
These plots indicated a pattern with a clear additional effect of
CMF/ goserelin versus goserelin alone or CMF alone
predominantly in the younger ages (<40 years) in the ER-
positive cohort (Figure 3).
discussion
With 12.1 years of median follow-up in this trial of pre- and
perimenopausal women with node-negative breast cancer, CMF
followed by goserelin significantly improved both 12-year DFS
and BCFI compared with either modality alone among patients
with ER-positive disease. These results are in line with the
previous report from this study at 7 years of follow-up [8],
though at that time the superiority of CMF followed by
goserelin versus either modality alone was not statistically
significant in the ER-positive cohort.
The superiority of adding CMF to goserelin in this study is
also consistent with results from the Early Breast Cancer
Trialists’ Collaborative Group overview that showed additional
benefit of chemoendocrine therapy compared with endocrine
therapy alone in hormone receptor-positive breast cancer [2].
However, the biological reason for the additional effect of
chemotherapy could not be addressed in the overview. In the
present study, the STEPP analysis with subpopulations of
different ages at diagnosis clearly shows a pattern with
additional treatment efficacy of CMF followed by goserelin in
patients at younger ages (<40 years of age) with ER-positive
disease. Amenorrhea rate was meticulously recorded. CMF
followed by goserelin clearly prolonged amenorrhea compared
with goserelin alone among patients <40 years [8] (Figure 4).
This suggests that the treatment efficacy may reflect prolonged
ovarian function suppression induced by CMF.
Ovarian function suppression as manifest by chemotherapy-
induced amenorrhea was associated with improved outcome in
patients with ER-positive node-positive breast cancer
participating in IBCSGTrial 13–93 [DFSHR (amenorrhea versus
no amenorrhea) = 0.59; 95% CI 0.35–1.00 based on a 1.5 year
landmark analysis for patients randomized to tamoxifen] [12].
By contrast, no association between amenorrhea and outcome
was seen in the ER-negative cohort inTrial 13–93 (DFSHR=1.58;
95% CI 0.72–3.45). These findings have recently been confirmed
with data from NSABP B-30 [13, 14]. While NSABP B-30
originally reported a positive association between amenorrhea
and outcome in the ER-negative cohort [13], no association was
seen in a subsequently published landmark analysis for this
cohort [14]. Similarly, in the present study, ovarian function
suppression alone was less effective than regimens containing
chemotherapy among patients with ER-negative disease.
If the benefit of chemotherapy in hormone receptor-positive
breast cancer in young patients in the present study is mediated
mainly through more prolonged ovarian function suppression,
this information would be highly clinically relevant since
suppression can be achieved without the toxic effects of
chemotherapy, which might not be needed for such patients.
Trials designed to address this question have proved unpopular
and have failed to meet their accrual goals. IBCSG Trial 11–93
randomized patients receiving ovarian function suppression
and tamoxifen to the addition of four cycles of adriamycin-
cyclophosphamide or to no chemotherapy, but only 174
patients were randomized. After a median follow-up of 10
years, no difference in outcome was seen between the two
Table 2. (Continued)
Total
patients
Total
events
5-year
BCFI % 6 SE
12-year
BCFI % 6 SE
HR Lower
95% CI
Upper
95% CI
P-value
ER2 age <40 Gos 20 7 75 6 10 64 6 11 C versus G 0.93 0.31 2.79 0.90
CMF 16 6 81 6 10 74 6 11 C/G versus G 1.03 0.36 2.94 0.96
CMF/Gos 20 7 80 6 9 65 6 11 C/G versus C 1.02 0.34 3.04 0.98
ER2 age ‡40 Gos 45 17 71 6 7 64 6 7 C versus G 0.77 0.39 1.52 0.45
CMF 52 16 81 6 5 70 6 6 C/G versus G 0.58 0.28 1.19 0.14
CMF/Gos 52 13 87 6 5 74 6 6 C/G versus C 0.74 0.35 1.53 0.41
CMF, cyclophosphamide, methotrexate and fluorouracil; CI, confidence interval; ER, estrogen receptor; Gos, goserelin; HR, hazard ratio; SE, standard error.
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groups [15]. Similarly, the PERCHE trial [16] was closed after 3
years with only 29 patients randomized.
The quality of life in this trial has previously been reported
[17]. The patients who received goserelin alone had less
deterioration in quality-of-life measures during the first 6
months compared with patients on CMF. Regarding hot
flushes, these symptoms closely followed the pattern of
amenorrhea in the three groups with prolonged symptoms of
hot flushes in the CMF–goserelin group compared with the
other groups, especially among patients <40 years.
A limitation of the present study is that goserelin alone for
2 years is not considered optimal endocrine therapy by today’s
standards. Tamoxifen was not included in the endocrine
therapy regimen because it was not routinely used in
premenopausal women when the trial was initiated.
Furthermore, the duration of ovarian function suppression
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Figure 1. Kaplan–Meier estimates of disease-free survival (A,D), overall survival (B,E), and breast cancer-free interval (C,F) by treatment according to
cohorts defined as estrogen receptor positive (A–C) and estrogen receptor negative (D–F) in the International Breast Cancer Study Group Trial VIII.
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achieved by 2 years of goserelin may be insufficient, especially
for patients under age 40 with ER-positive node-negative
disease, who experienced a high risk of recurrence in the
goserelin alone group. Davidson et al. showed a significant
benefit of adding tamoxifen (T) to CAF-Z (cyclophosphamide,
adriamycin, fluorouracil–goserelin), with a 9-year DFS of 57%
for CAF, 60% for CAF-Z, and 67% for CAF-ZT among
premenopausal patients with hormone receptor-positive node-
positive breast cancer [18]. Goserelin (Z) andTwere administered
for a duration of 5 years. Whether adding ovarian function
suppression to tamoxifen improves outcome remains an open
question, which is being addressed in the ongoing Suppression of
Ovarian Function Trial study [19]. It is also possible that CMF,
used in the current study, is slightly inferior to newer
chemotherapy regimens that include anthracyclines or taxanes for
some groups of patients. Since both the endocrine treatment and
Figure 2. Kaplan–Meier estimates of disease-free survival (A,D), overall survival (B,E), and breast cancer free interval (C,F) by treatment according to age
cohorts within the estrogen receptor-positive cohort in IBCSG Trial VIII. The younger (<40 years) cohort is on the left (A–C).
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the chemotherapy in the present trial differ from the current
optimal standard treatments, the results cannot directly be applied
in the management of breast cancer patients today.
The ongoing Trial Assigning Individualized Options for
Treatments Rx-trial addresses the value of adding chemotherapy
to endocrine therapy alone [20]. Hormone receptor-positive
breast cancers in both pre- and postmenopausal women are
assessed with Oncotype-DX. Patients with intermediate
recurrence scores are randomized to either chemoendocrine
therapy or endocrine therapy alone. The Oncotype-DX
recurrence score is complex and involves genes representing both
human epidermal growth factor receptor 2 (HER2) and steroid
hormone receptor pathways as well as proliferation genes. The
group of patients with an intermediate recurrence score may be
biologically heterogeneous with different expected additional
effect of chemotherapy.
Viale et al. [21] have published STEPP analyses with 5-year
DFS according to different overlapping ER levels in IBCSG
Trials VIII and IX. Low levels of ER were predictive of the
benefit of adding chemotherapy. For premenopausal women
with ER-present disease, variability in the pattern of treatment
effect differences between CMF/goserelin and CMF alone or
goserelin alone was suggested. The pattern in this update was
similar to that report (data not shown).
In a recent publication involving the central review of HER2
in IBCSG Trials VIII and IX, Colleoni et al. [22] showed no
clear benefit of CMF in endocrine receptor present patients
[HR (CMF versus no CMF) 0.90, 95% CI 0.74–1.11] but
a significant benefit in the triple-negative group (HR 0.46, 95%
CI 0.29–0.73). The magnitude of CMF efficacy seemed to be
lower in the HER2-positive/endocrine receptor absent group
(HR 0.58, 95% CI 0.29–1.17) and in the small group of HER2-
positive/endocrine receptor present group (n = 220, HR 0.73,
95% CI 0.42–1.25).
In conclusion, at 12 years of median follow-up, CMF followed
by goserelin resulted in significant improvement of DFS and
BCFI for premenopausal patients with ER-positive node-
negative breast cancer compared with either modality alone. The
effect was most pronounced in patients below <40 years of age.
This effect may be mediated by the prolonged ovarian function
suppression induced byCMF. To sort out the additional effects of
chemotherapy compared to endocrine therapy alone,
a randomized comparison in a pure highly endocrine responsive
patient population is still needed to ascertain whether such
patients can safely be spared the toxic effects of chemotherapy.
Figure 3. Subpopulation Treatment Effect Patten Plot showing 5-year (A)
and 12-year (B) DFS percentages by treatment group according to
overlapping subpopulations of age at randomization for 851 patients in the
estrogen receptor-positive cohort.
Table 3. Multivariable Cox proportional hazards regression analyses on
disease-free survival for estrogen receptor (ER)-positive and -negative
cohorts
Cohort Hazard ratio
(95% CI)
P value
ER-positive cohort (n = 851)
CMF versus goserelin 1.00 (0.74–1.36) 0.99
CMF/goserelin versus goserelin 0.71 (0.51–1.00) 0.05
CMF/goserelin versus CMF 0.72 (0.51–1.00) 0.05
Age <40 versus ‡40 1.50 (1.10–2.06) 0.01
Primary surgical treatment 0.0002
BCS without RT versus Mast 2.39 (1.45–3.94)
BCS with RT versus Mast 0.83 (0.63–1.11)
Tumor size (cm) 0.19
1.1–2.0 versus £1 1.14 (0.73–1.79)
>2.1 versus £1 1.43 (0.90–2.27)
Grade 0.0001
2 versus 1 1.75 (1.14–2.70)
3 versus 1 2.54 (1.63–3.97)
ER-negative cohort (n = 205)
CMF versus goserelin 0.81 (0.46–1.42) 0.46
CMF/goserelin versus goserelin 0.71 (0.40–1.24) 0.23
CMF/goserelin versus CMF 0.87 (0.49–1.55) 0.64
Age <40 versus ‡40 0.95 (0.56–1.61) 0.84
Primary surgical treatment 0.69
BCS without RT versus Mast 1.46 (0.61–3.52)
BCS with RT versus Mast 1.04 (0.63–1.73)
Tumor size (cm) 0.31
1.1–2.0 versus £1 0.55 (0.26–1.19)
>2.1 versus £1 0.63 (0.29–1.38)
Grade 0.24
2 versus 1 1.32 (0.30–5.72)
3 versus 1 0.82 (0.20–3.39)
CMF, cyclophosphamide, methotrexate and fluorouracil; CI, confidence
interval; RT, radiation therapy; BCS, breast-conserving surgery; Mast,
mastectomy.
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